Zhitong Finance App News, Sunshine Nuohe (688621.SH) issued an announcement. Recently, Chengdu Nuohe Shengtai Biotechnology Co., Ltd. (“Novo Shengtai”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for STC009 injection for the company's ongoing research project was approved. The intended declared indication for STC009 injection is secondary hyperparathyroidism (SHPT).

Zhitong Finance App News, Sunshine Nuohe (688621.SH) issued an announcement. Recently, Chengdu Nuohe Shengtai Biotechnology Co., Ltd. (“Novo Shengtai”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for STC009 injection for the company's ongoing research project was approved. The intended declared indication for STC009 injection is secondary hyperparathyroidism (SHPT).